Conditions: Diabetic Nephropathy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 60
Healthy volunteers: no

Brief summary:
The purpose of this two-part study is to investigate the safety, tolerability and efficacy of LY3016859 after multiple intravenous (IV) dosing's in participants with diabetic nephropathy (DN). Part A will be dose escalation for safety and tolerability and Part B will evaluate Proteinuria.

Detailed description:

Arms:
arm 1: Part A: Placebo administered by 60 minute Intravenous (IV) infusion at Week 1 and Week 4. arm 2: Part A: 10 milligram (mg) LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4. arm 3: Part A: 100 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4. arm 4: Part A: 750 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4. arm 5: Part B: Placebo administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13. arm 6: Part B: 50 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13. arm 7: Part B: 250 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13. arm 8: Part B: 750 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.

Interventions: intervention 1: Placebo intervention 2: LY3016859
Intervention descriptions: intervention 1: Administered IV intervention 2: Administered IV

Protocol document: